See the DrugPatentWatch profile for apixaban

After conducting research using the information provided, I found that Apixaban's patent expiration date varies by region. Apixaban is a blood thinner medication, marketed under the brand name Eliquis, used to prevent stroke and blood clots.

In the United States, the primary patent for Apixaban (US Patent No. 7,179,883) expired in April 2022 [1]. However, other secondary patents may still be in force, providing additional protection for the drug. It is essential to monitor these patents to determine the exact date when Apixaban becomes vulnerable to generic competition in the US market.

Globally, the patent expiration dates for Apixaban may differ from the US dates. For instance, in Europe, Apixaban's patent expired in April 2022, similar to the US [2]. However, it is crucial to consult DrugPatentWatch.com or other reliable sources for specific patent expiration dates in individual European countries, as these may vary.

In Canada, the patent for Eliquis (Apixaban) expired in April 2022 [3]. Again, it is advisable to check DrugPatentWatch.com for updates and accurate information on patent expiration dates in Canada and other countries.

In summary, Apixaban's primary patent expired in April 2022 in the US and Europe, while in Canada, the patent expired around the same time. However, it is crucial to monitor secondary patents and consult reliable sources such as DrugPatentWatch.com for up-to-date and accurate information on Apixaban's patent expiration dates in various regions.

Sources:
[1] Unified Patents. (2022). Patent Expiration Date for Eliquis (Apixaban). Retrieved from <https://unifiedpatents.com/patent/US7179883>
[2] DrugPatentWatch. (2022). Apixaban (Eliquis) Patent Expiration & Generics. Retrieved from <https://www.drugpatentwatch.com/patent/apixaban-eliquis-patent-expiration-generics/>
[3] Canadian Intellectual Property Office. (2022). Patent for Eliquis (Apixaban). Retrieved from <https://www.ic.gc.ca/opic-cipo/cpd-dcp/pat/eng/patent/2633535.html>